A new treatment for TTP?

Nephrology Dialysis Transplantation

Volumn 21, Issue 3, 2006, Pages 577-579

  Fakhouri, Fadi ^a   Deroure, Benjamin ^a   Hummel, Aurélie ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Monoclonal antibody; Rituximab; Thrombotic thrombocytopenic purpura (TTP)

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; EDITORIAL; ENZYME ACTIVITY; GENE MUTATION; HUMAN; IMMUNOADSORPTION; LONG TERM CARE; MORTALITY; PATHOPHYSIOLOGY; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; SPLENECTOMY; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC FACTORS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; TREATMENT OUTCOME;

EID: 33644868269     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfk042     Document Type: Editorial

References (15)

1. Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology (Am Soc Hemato Educ Program) 2004; 407-423
2. Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003; 14: 1072-1081
3. Rock GA. Management of thrombotic thrombocytopenic purpura. Br J Haematol 2000; 109: 496-507
4. O'Connor NT, O'Shea MJ, Hill LF. Vincristine for thrombotic thrombocytopenic purpura. Lancet 1992; 340: 490
5. Durand JM, Lefevre P, Kaplanski G et al. Vincristine for thrombotic thrombocytopenic purpura. Lancet 1992; 340: 977-978
6. Durand JM, Lefevre P, Kaplanski G et al. Ineffectiveness of high-dose intravenous gammaglobulin infusion in thrombotic thrombocytopenic purpura. Am J Hematol 1993; 42: 234
7. Udvardy M, Rak K. Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura. Lancet 1990; 336: 1508-1509
8. Crowther MA, Heddle N, Hayward CP et al. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura. Ann Intern Med 1996; 125: 294-296
9. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003; 14: 520-535
10. Quartier P, Brethon B, Philippet P et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358: 1511-1513
11. De Vita S, Zaja F, Sacco S et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells. Arthritis Rheum 2002; 46: 2029-2033
12. Leandro MJ, Edwards JC, Cambridge G et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-2677
13. Yomtovian R, Niklinski W, Silver B et al. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: A case report and review of the literature. Br J Haematol 2004; 124: 787-795
14. Barbot J, Costa E, Guerra M et al. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease. Br J Haematol 2001; 113: 649-651
15. Zheng XL, Kaufman RM, Goodnough LT et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-4049